Trazodone, [Fig.1] a triazolopyridine derivative belonging to the class of serotonin antagonist an reuptake inhibitors (SARI), is used in the treatment of depression  and is currently approved by the FDA to treat major depression . Trazodone has been branded as Desyrel – trazadone hydrochloride (HCl), and its uses, besides its antidepressant activity, include treating medical and psychiatric disorders , along with the treatment of post-traumatic stress disorder (PTSD), insomnia, anxiety disorders, obsessive compulsive disorders (OCD), eating disorders, abuse of substances, impediments in cognitive functioning, sexual dysfunction, and particularly in rehabilitation following acute ischemic stroke [3; 4]. Specifically, trazodone HCl [Fig.1] is considered an anti-depressant agent. The way trazodone works is through its antagonism of the serotonin receptor (5-HT2A), alpha 1 and histamine H1 receptors, and this permits the drugs hypnotic effects (at low doses), whilst a high trazodone dose blocks serotonin transporter (SERT) and 5-HT2A allowing for its antidepressant activity . In addition, due to trazodone’s strong antagonistic action at serotonergic type 2 (5-HT2) receptors it is known to quickly improve sleep [5; 1]. Further, trazodone’s pharmacological mode of action is such that a very low dose – 1mg trazodone – can block half of the brain’s 5-HT2A receptors .
There are no reviews yet.